| Literature DB >> 25123558 |
Wagner A Lucena1, Patrícia B Pelegrini2, Diogo Martins-de-Sa3, Fernando C A Fonseca4, Jose E Gomes5, Leonardo L P de Macedo6, Maria Cristina M da Silva7, Raquel S Oliveira8, Maria F Grossi-de-Sa9.
Abstract
Bacillus thuringiensis (Bt) is a gram-positive spore-forming soil bacterium that is distributed worldwide. Originally recognized as a pathogen of the silkworm, several strains were found on epizootic events in insect pests. In the 1960s, Bt began to be successfully used to control insect pests in agriculture, particularly because of its specificity, which reflects directly on their lack of cytotoxicity to human health, non-target organisms and the environment. Since the introduction of transgenic plants expressing Bt genes in the mid-1980s, numerous methodologies have been used to search for and improve toxins derived from native Bt strains. These improvements directly influence the increase in productivity and the decreased use of chemical insecticides on Bt-crops. Recently, DNA shuffling and in silico evaluations are emerging as promising tools for the development and exploration of mutant Bt toxins with enhanced activity against target insect pests. In this report, we describe natural and in vitro evolution of Cry toxins, as well as their relevance in the mechanism of action for insect control. Moreover, the use of DNA shuffling to improve two Bt toxins will be discussed together with in silico analyses of the generated mutations to evaluate their potential effect on protein structure and cytotoxicity.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25123558 PMCID: PMC4147589 DOI: 10.3390/toxins6082393
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Structure of an activated Cry1Ab toxin. The three Domains are colored as follows: Domain I (red), Domain II (green), and Domain III (blue). Loop 1 is shown in cyan, loop 2 is shown in magenta, loop 3 is shown in black and loop α8 is shown in orange.
Site-directed mutations of Cry1Aa, Cry1Ab and Cry1Ac and their influence on toxins’ function against insect pests.
| Toxin | Mutation | Region | Characteristic | Molecular effect | Toxicity | Reference |
|---|---|---|---|---|---|---|
|
| L126C | Helix α4 (domain I) | Reduced capacity to form pores | Low influx of ions | Extremely reduced | [ |
| R127C | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | ||
| M130C | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | ||
| R131C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| I132C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Reduced | ||
| Q133C | Helix α4 (domain I) | Reduced capacity to form pores | Low influx of ions | Extremely reduced | ||
| F134C | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Reduced | ||
| N135C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| M137C | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | ||
| N138C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| S139C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Reduced | ||
| A140C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| L141C | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | ||
| T142C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| A144C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| I145C | Helix α4 (domain I) | Reduced capacity to form pores | Low influx of ions | Slightly reduced | ||
| P146C | Helix α4 (domain I) | Reduced capacity to form pores | Low influx of ions | Extremely reduced | ||
| L147C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| A149C | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | ||
| R127E | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | [ | |
| R127N | Helix α4 (domain I) | Increased capacity to form pores | Increased influx of ions | Slightly reduced | ||
| E128C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Slightly reduced | ||
| E129C | Helix α4 (domain I) | Abolished capacity to form pores | n/a | Extremely reduced | ||
| E129K | Helix α4 (domain I) | Abolished capacity to form pores | n/a | Extremely reduced | ||
| R131D | Helix α4 (domain I) | Increased capacity to form pores | Low influx of ions | Extremely reduced | ||
| R131E | Helix α4 (domain I) | Highly reduced capacity to form pores | Low influx of ions | Slightly reduced | ||
| R131H | Helix α4 (domain I) | Highly reduced capacity to form pores | Low influx of ions | Extremely reduced | ||
| R131Q | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Reduced | ||
| D136C | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| D136N | Helix α4 (domain I) | Highly reduced capacity to form pores | Extremely low influx of ions | Extremely reduced | ||
| D136Y | Helix α4 (domain I) | Abolished capacity to form pores | n/a | Extremely reduced | ||
| T142D | Helix α4 (domain I) | Abolished capacity to form pores | n/a | Extremely reduced | ||
| T143D | Helix α4 (domain I) | Abolished capacity to form pores | n/a | Extremely reduced | ||
| Y445C | Loop 3 (domain II) | Reduced Bt-R175 binding capacity | n/a | Extremely reduced | [ | |
|
| R99E | Helix α3 (domain I) | No oligomer formation | No membrane insertion | Extremely reduced | [ |
| L100E | Helix α3 (domain I) | No significant alteration | No significant alteration | No significant alteration | ||
| Y107E | Helix α3 (domain I) | No oligomer formation | No membrane insertion | Extremely reduced | ||
| I200D | Helix α6 (domain I) | No significant alteration | No significant alteration | No significant alteration | ||
| Y203D | Helix α6 (domain I) | No significant alteration | No significant alteration | No significant alteration | ||
| R99E | Helix α3 (domain I) | No oligomer formation | No membrane insertion | Reduced | [ | |
| E129K | Helix α4 (domain I) | Dominant negative effect | Low capacity to insert into cell membrane | Extremely reduced | ||
| N135C | Helix α4 (domain I) | Dominant negative effect | Low capacity to insert into cell membrane | Extremely reduced | ||
| D136N | Helix α4 (domain I) | No competition with wild-type Cry1Ab | Low capacity to insert into cell membrane | Slightly increased | ||
| A140K | Helix α4 (domain I) | No competition with wild-type Cry1Ab | Low capacity to insert into cell membrane | Slightly increased | ||
| T142C | Helix α4 (domain I) | Dominant negative effect | Low capacity to insert into cell membrane | Extremely reduced | ||
| T143D | Helix α4 (domain I) | Dominant negative effect | Low capacity to insert into cell membrane | Extremely reduced | ||
| D136N, T143D | Helix α4 (domain I) | Dominant negative effect | Low capacity to insert into cell membrane | Extremely reduced | ||
| E129K, D136N | Helix α4 (domain I) | Dominant negative effect | Low capacity to insert into cell membrane | Extremely reduced | [ | |
| G439D | Loop 3 (domain II) | No binding to receptor | Low capacity to insert into cell membrane | No significant alteration | ||
| V171C | Helix α5 (domain I) | Reduced toxin folding | Increased capacity to insert into cell membrane | Highly increased | ||
| L157C | Helix α5 (domain I) | Reduced toxin folding | Increased capacity to insert into cell membrane | Increased | ||
| N372A | Loop 2 (domain II) | Increased biding capacity to BBMVs | n/a | Highly increased | [ | |
| N372G | Loop 2 (domain II) | Increased biding capacity to BBMVs | n/a | Highly increased | ||
| N372del | Loop 2 (domain II) | Highly reduced binding capacity to BBMVs | n/a | Extremely reduced | ||
| N372A, A282G, L283S | Loop2, Loop α8a, Loop α8 (domain II) | Increased biding capacity to BBMVs | n/a | Highly increased | ||
| Y153D | Loop between α4 and α5 (domain I) | Weaker membrane insertion | n/a | Reduced | [ | |
| G282A, S283L | 8 Loop (domain II) | Reduced binding to receptor | n/a | Highly reduced | ||
| R345A, Y350A, Y351A | Loop 1 (Domain II) | Reduced binding to receptor | n/a | Slightly reduced | ||
| I373A | Loop 2 (Domain II) | Structure instability | n/a | Reduced | ||
| F371A, G374A | Loop 2 (Domain II) | Alters binding to membrane | Increase in dissociation from the membrane | Highly reduced | ||
| F440A, G439A | Loop 3 (Domain II) | Affects binding to receptor | n/a | Highly reduced | ||
|
| N135Q | Helix α4 (domain I) | No oligomer formation | No membrane insertion | Extremely reduced | [ |
| Q509A | GalNac binding site (domain III) | Highly reduced binding capacity to APN | n/a | Slightly reduced | [ | |
| R511A | GalNac binding site (domain III) | Highly reduced binding capacity to APN | n/a | Slightly reduced | ||
| Y513A | GalNac binding site (domain III) | Highly reduced binding capacity to APN | n/a | Slightly reduced | ||
| Q509A | GalNac binding site (domain III) | No significant alteration | n/a | Reduced | [ | |
| N510A | GalNac binding site (domain III) | Highly reduced binding capacity to ALP | n/a | Reduced | ||
| R511A | GalNac binding site (domain III) | No significant alteration | n/a | Reduced | ||
| Y513A | GalNac binding site (domain III) | Highly reduced binding capacity to ALP | n/a | Extremely reduced | ||
| W545A | GalNac binding site (domain III) | Highly reduced binding capacity to ALP | n/a | Extremely reduced | ||
| T524N | Loop β16-β17 (domain III) | n/a | n/a | Increased | [ |
Figure 2Mortality of T. l. licus following ingestion of Cry1Ia12 toxin and its variants (3 µg each). The results represent insect mortality after 5 days of a diet containing each of the respective proteins.
Mutations present in Cry1Ia12 variants. Deletions are indicated by del and insertions by ins.
| Variant | Mutation | Domain | Reference |
|---|---|---|---|
|
| D233N, E639G | I, III | [ |
|
| D233N | I | [ |
|
| I116T, L266F, K580R | I, I, III | [ |
|
| M45V | [ | |
| D233N | I | ||
|
| S84G, R159K, G380R | I, I, II | This report |
|
| S84G | I | This report |
| R159K | I | ||
| L212del | I | ||
| S213del | I | ||
| Q413S | II | ||
| P414T | II | ||
| P419L | II | ||
|
| S84G | I | This report |
|
| S84G | I | This report |
| R159K | I | ||
| G380R | II | ||
| K427ins | II |
Figure 3Tertiary structure of Cry1Ia12. α-Helices colored red correspond to Domain I of the toxin. β-Sheets colored yellow color correspond to Domains II and III. Blue spheres represent the mutated residues from DNA shuffling involved in binding to receptors.
Figure 4Alignment of 15 Cry toxins: Cry1Aa (AAP40639.1), Cry1Ab (AEV45790.1), Cry1Ac (ACC86135.1), Cry1Ia12 (ADB02877.1), Cry1F (ACD50893.1), Cry1Ba (AAK63251.1), Cry11Aa (YP_001573776.1), Cry8Ea1 (AAQ73470.1), Cry8Ka1 (ACQ99188.1), Cry3A (ABY49136.1), Cry9Ea (ADE60738.1), Cry2Ab (ACC86136.1), Cry4Aa (YP_001573833.1), Cry4Ba (YP_001573790.1) and Cry5Aa (Q45760.1). Polarity conserved residues in mutation regions are highlighted in gray, and residues mutated by DNA shuffling in Cry1Ia12 are depicted in bold red [13] and bold magenta (unpublished results). Deletions or additions of residues are further highlighted in black. Inserts A, B C, D, E, F, G and H correspond to different regions in the alignment.
Figure 5Detailed view of D233 from variant 2. (A) Distance between the NZ atom of K600 and OD2 of D233 (4.8 Å) in wild-type Cry1Ia12; (B) ABPS-SEP of wild-type Cry1Ia12 depicting the proximity between K600, D598 and D233; (C) ABPS-SEP of variant 2 depicting the displacement of K600 from the salt bridge interaction with N233 and D598. The inset in the upper right corner represents the entire Cry1Ia12 structure.
Figure 6(A) Tertiary structure of Cry1Ia12. Domain I is colored red, whereas Domains II and III are colored yellow; (B) Detailed view of the interaction between L266 within the toxin and I60 in helix α-1. Distances are shown as dashed lines and are measured in angstroms (Å). α-Helix secondary structure is represented in red, and the protein surface is represented in green; (C) Detailed view of I116 interactions with the hydrophobic residues M105, A120, P184 and L185 in Domain I. Distances are shown as dashed lines and measured in angstroms (Å). α-Helices are colored red, and loops are colored green; (D) Tertiary structure of Cry1Ia12. Domain I is colored red, whereas Domains II and III are colored yellow.
Figure 7The tertiary structure of Cry8Ka5. Roman numbers indicate the Domains of the Cry toxin. Mutated residues (R82Q, R508G, and K538E) observed in the three Domains are shown in a detailed view.
Transgenic plants expressing toxins from Cry1A family for insect resistance. Source: [102].
| Plant | Company | Event | Year/Country regulatory approval | Toxin(s) inserted | Insect species for resistance |
|---|---|---|---|---|---|
|
| Monsanto Company | MON87701 | Canada (2010); United States (2011) | Cry1Ac | |
| MON87701/MON89788 | Colombia (2012) | Cry1Ac, CP4 epsps | Lepidopteran pests | ||
|
| Dow AgroSciences LLC | 3006-210-23 | Mexico (2004); United States (2004); Canada, Japan (2005) | Cry1Ac | |
| Calgene Inc. | 31807/31808 | United States (1997/1998); Canada, Japan (1998/1999) | Cry1Ac | Lepidopteran pests | |
| Syngenta Seeds, Inc. | COT67B | Australia, United States (2009) | Cry1Ab | ||
| Dow AgroSciences LLC | DAS-21Ø23-5/DAS-24236-5 | Mexico, United States (2004); Australia (2005); Japan (2005); Korea (2005/2008); Brazil (2009) | Cry1Ac, Cry1F | ||
| DAS-21Ø23-5/DAS-24236-5/MON-Ø1445-2 | Mexico (2005); Korea (2006); Japan (2006) | Cry1Ac, Cry1F | |||
| DAS-21Ø23-5/DAS-24236-5/MON88913 | Japan, Korea, Mexico (2006) | Cry1Ac, Cry1F | |||
| JK Agri Genetics LTd (India) | Event-1 | India (2006) | Cry1Ac | ||
| Bayer CropScience | LLCotton25/MON15985 | Japan (2006/2007); Korea (2007/2008); Mexico (2008) | Cry1Ac, Cry2Ab | ||
| Monsanto Company | MON15985 | Australia, United States (2002); Japan (2002/2003); Canada, Mexico, Philippines, South Africa (2003); Korea (2003/2004) European Union (2005); China, India (2006); Burkina Faso (2008); Brazil, Colombia (2009) | Cry1Ac, Cry2Ab2 | ||
| MON-15985-7/MON-Ø1445-2 | Australia (2002); Korea (2004/2008); Philippines (2004); European Union, Japan (2005); Mexico (2006) | Cry1Ac, Cry2Ab | |||
| MON-ØØ531-6/MON-Ø1445-2 | Mexico (2002); Australia (2003); Japan, Philippines (2004); Korea (2004/2008); European Union, South Africa (2005); Colombia (2008); Argentina, Brazil (2009) | Cry1Ac | |||
|
| Monsanto Company | MON15985/MON88913 | Japan (2005/2006); Australia, Mexico, Philippines (2006); Korea (2006/2008); South Africa (2007); Colombia (2010) | Cry1Ac, Cry2Ab | |
| MON531/757/1076 | United States (1995); Australia, Canada (1996); Japan, Mexico, South Africa (1997); Argentina (1998); India (2002); Colombia (2003); Korea (2003/2004); China, Philippines (2004); Brazil, European Union (2005) | Cry1Ac | |||
|
| Monsanto Company | 5345 | United States (1998); Canada (2000) | Cry1Ac | |
|
| Syngenta Seeds, Inc. | 176 | United States (1995); Canada (1995/1996); Japan (1996); Argentina (1996/1998); European Union, The Netherlands, Switzerland, United Kingdom (1997); Australia, South Africa (2001); Philippines (2003); Korea (2003/2006); China, Taiwan (2004) | Cry1Ab |
|
| BT11 (X4334CBR, X4734CBR) | Canada, Japan, United States (1996); European Union, Switzerland, United Kingdom (1998); Argentina, Australia (2001); South Africa (2002); Korea (2003/2006); Russia (2003); China, Taiwan, Uruguay (2004); Philippines (2005); Brazil, Mexico (2007); Colombia (2008/2009) | Cry1Ab |
| ||
| BT11/GA21 | Canada (2005); Korea (2006/2008); Japan, Mexico, Philippines (2007); Argentina, Brazil (2009); Uruguay (2011); Colombia (2012) | Cry1Ab, Vip3Aa20 | |||
| BTT11/GA21/MIR162 | Brazil (2011); Colombia (2012) | Cry1Ab, Vip3Aa20 | |||
| BT11/MR162 | United States (2009) | Cry1Ab, Vip3Aa20 | |||
|
| Syngenta Seeds, Inc. | BT11/MIR162/MIR604 | United States (2009) | Cry1Ab, Vip3Aa20 | |
| BT11/MIR162/MIR604/GA21 | Colombia (2012) | Cry1Ab, mCry3A,Vip3a20 | |||
| BT11/MIR604 | Canada, Japan, Korea, Mexico, Philippines (2007); Colombia (2012) | Cry1Ab, mCry3A | |||
| BT11/MIR604/GA21 | Canada, Japan (2007); Korea, Mexico, Philippines (2008); | Cry1Ab | |||
| DeKalb Genetics Corporation | DBT418 | Canada, United States (1997); Japan (1999); Australia (2002); Philippines, Taiwan (2003); Korea (2004) | Cry1Ac |
| |
| Monsanto Company | GA21/MON810 | Japan, South Africa (2003); Korea, Philippines (2004); European Union (2005) | Cry1Ab | ||
| MON80100 | United States (1996) | Cry1Ab |
| ||
| MON802 | United States (1996/1997); Canada, Japan (1997) | Cry1Ab |
| ||
| MON809 | Canada, United States (1996); Japan (1997/1998) | Cry1Ab |
| ||
| MON810 | United States (1995/1996); Japan (1996/1997); Canada, South Africa (1997); Argentina, European Union (1998); Australia, Switzerland (2000); Mexico, Philippines, Taiwan (2002); Korea (2002/2004); Colombia, Uruguay (2003); China (2004); Brazil (2007) | Cry1Ab |
| ||
| MON810/LY038 | Philippines (2006); Japan (2007) | Cry1Ab |
| ||
| MON810/MON88017 | Japan (2005); Canada, Korea, Mexico (2006); Taiwan (2009); Colombia (2011) | Cry1Ab, Cry3Bb1 | |||
|
| Monsanto Company | MON863/MON810 | Japan, Korea, Philippines (2004); European Union (2005); Mexico (2006) | Cry1Ab, Cry3Bb1 | |
| MON863/MON810/NK603 | Canada, Japan, Korea (2004); Philippines (2004/2005); Mexico (2006); Taiwan (2009) | Cry1Ab, Cry3Bb1 | |||
| MON89034 | Japan, United States (2007/2008); Australia, Canada, Taiwan (2008); Brazil, European Union, Korea, Philippines (2009); Colombia (2010) | Cry1A.105,Cry2Ab | |||
| MON89034/MON88017 | Japan (2008); Korea, Philippines, Taiwan (2009); Argentina (2010); Colombia (2011) | Cry1A.105,Cry2Ab, Cry3Bb1 | |||
| Monsanto Company and Mycogen Seeds c/o Dow LLC | MON89034/TC1507/MON88017/DAS-59122-7 | Canada, Japan, Korea, Taiwan, United States (2009); Colombia, Mexico, Philippines (2010) | Cry1A.105, Cry1Fa2, Cry2Ab, Cry3Bb1,Cry34Ab1, Cry35Ab1 | ||
| Monsanto Company | NK603/MON810 | Canada (2001); Japan, Korea, Mexico, Philippines (2004); Argentina (2005/2007); European Union (2007); Taiwan, Brazil, Colombia, El Salvador (2009); Uruguay (2011) | Cry1Ab | ||
| Bayer CropScience (Aventis CropScience (AgrEvo)) | T25/MON810 | Japan (2003); Colombia (2012) | Cry1Ab | ||
| DuPont Pioneer | TC1507/MON810 | Brazil (2011); Colombia (2012); Argentina (2013) | Cry1Ab,Cry1Fa2 | Lepidopteran pests | |
| TC1507/MON810/NK603 | Canada (2011); Colombia (2012); Argentina (2013) | Cry1Ab, Cry1Fa2 | Lepidopteran pests |